These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37283627)

  • 1. Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial.
    Wada T; Hibino M; Aono H; Kyoda S; Iwadate Y; Shishido E; Ikeda K; Kinoshita N; Matsuda Y; Otani S; Kameda R; Matoba K; Nonaka M; Maeda M; Kumagai Y; Ako J; Shichiri M; Naoki K; Katagiri M; Takaso M; Iwamura M; Katayama K; Miyatsuka T; Orihashi Y; Yamaoka K;
    Front Med (Lausanne); 2023; 10():1139046. PubMed ID: 37283627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
    Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
    Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial.
    Manomaipiboon A; Pholtawornkulchai K; Poopipatpab S; Suraamornkul S; Maneerit J; Ruksakul W; Phumisantiphong U; Trakarnvanich T
    Trials; 2022 Aug; 23(1):714. PubMed ID: 36028897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
    Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Achinelli F; Guglielmone HA; Ojeda J; Medina F; Farizano Salazar D; Andino G; Ruiz Diaz NE; Kawerin P; Meza E; Dellamea S; Aquino A; Flores V; Martemucci CN; Vernengo MM; Martinez SM; Segovia JE; Aguirre MG
    Trials; 2020 Nov; 21(1):965. PubMed ID: 33234158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erratum: Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial.
    Frontiers Production Office
    Front Med (Lausanne); 2023; 10():1289307. PubMed ID: 37809340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial.
    Mohan A; Tiwari P; Suri TM; Mittal S; Patel A; Jain A; Velpandian T; Das US; Boppana TK; Pandey RM; Shelke SS; Singh AR; Bhatnagar S; Masih S; Mahajan S; Dwivedi T; Sahoo B; Pandit A; Bhopale S; Vig S; Gupta R; Madan K; Hadda V; Gupta N; Garg R; Meena VP; Guleria R
    J Infect Chemother; 2021 Dec; 27(12):1743-1749. PubMed ID: 34483029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ivermectin for preventing and treating COVID-19.
    Popp M; Reis S; Schießer S; Hausinger RI; Stegemann M; Metzendorf MI; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD015017. PubMed ID: 35726131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of single-dose and double-dose ivermectin early treatment in preventing progression to hospitalization in mild COVID-19: A multi-arm, parallel-group randomized, double-blind, placebo-controlled trial.
    Mirahmadizadeh A; Semati A; Heiran A; Ebrahimi M; Hemmati A; Karimi M; Basir S; Zare M; Charlys da Costa A; Zeinali M; Sargolzaee M; Eilami O
    Respirology; 2022 Sep; 27(9):758-766. PubMed ID: 35738778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial.
    Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Medina MF; Achinelli F; Guglielmone HA; Ojeda J; Farizano Salazar D; Andino G; Kawerin P; Dellamea S; Aquino AC; Flores V; Martemucci CN; Martinez SM; Segovia JE; Reynoso PI; Sosa NC; Robledo ME; Guarrochena JM; Vernengo MM; Ruiz Diaz N; Meza E; Aguirre MG
    BMC Infect Dis; 2021 Jul; 21(1):635. PubMed ID: 34215210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ivermectin for preventing and treating COVID-19.
    Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
    Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Ivermectin 600 μg/kg for 6 days vs Placebo on Time to Sustained Recovery in Outpatients with Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Naggie S; Boulware DR; Lindsell CJ; Stewart TG; Lim SC; Cohen J; Kavtaradze D; Amon AP; Gabriel A; Gentile N; Felker GM; Rothman RL; Jayaweera D; McCarthy MW; Sulkowski M; Wilson S; DeLong A; Remaly A; Wilder R; Collins S; Dunsmore SE; Adam SJ; Thicklin F; Hanna GJ; Ginde AA; Castro M; McTigue K; Shenkman E; Hernandez AF;
    medRxiv; 2022 Dec; ():. PubMed ID: 36561174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India.
    Ravikirti ; Roy R; Pattadar C; Raj R; Agarwal N; Biswas B; Manjhi PK; Rai DK; Shyama ; Kumar A; Sarfaraz A
    J Pharm Pharm Sci; 2021; 24():343-350. PubMed ID: 34265236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Naggie S; Boulware DR; Lindsell CJ; Stewart TG; Gentile N; Collins S; McCarthy MW; Jayaweera D; Castro M; Sulkowski M; McTigue K; Thicklin F; Felker GM; Ginde AA; Bramante CT; Slandzicki AJ; Gabriel A; Shah NS; Lenert LA; Dunsmore SE; Adam SJ; DeLong A; Hanna G; Remaly A; Wilder R; Wilson S; Shenkman E; Hernandez AF;
    JAMA; 2022 Oct; 328(16):1595-1603. PubMed ID: 36269852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial.
    Mahmud R; Rahman MM; Alam I; Ahmed KGU; Kabir AKMH; Sayeed SKJB; Rassel MA; Monayem FB; Islam MS; Islam MM; Barshan AD; Hoque MM; Mallik MU; Yusuf MA; Hossain MZ
    J Int Med Res; 2021 May; 49(5):3000605211013550. PubMed ID: 33983065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial.
    Naggie S; Boulware DR; Lindsell CJ; Stewart TG; Slandzicki AJ; Lim SC; Cohen J; Kavtaradze D; Amon AP; Gabriel A; Gentile N; Felker GM; Jayaweera D; McCarthy MW; Sulkowski M; Rothman RL; Wilson S; DeLong A; Remaly A; Wilder R; Collins S; Dunsmore SE; Adam SJ; Thicklin F; Hanna GJ; Ginde AA; Castro M; McTigue K; Shenkman E; Hernandez AF;
    JAMA; 2023 Mar; 329(11):888-897. PubMed ID: 36807465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial.
    Chaccour C; Casellas A; Blanco-Di Matteo A; Pineda I; Fernandez-Montero A; Ruiz-Castillo P; Richardson MA; Rodríguez-Mateos M; Jordán-Iborra C; Brew J; Carmona-Torre F; Giráldez M; Laso E; Gabaldón-Figueira JC; Dobaño C; Moncunill G; Yuste JR; Del Pozo JL; Rabinovich NR; Schöning V; Hammann F; Reina G; Sadaba B; Fernández-Alonso M
    EClinicalMedicine; 2021 Feb; 32():100720. PubMed ID: 33495752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial.
    López-Medina E; López P; Hurtado IC; Dávalos DM; Ramirez O; Martínez E; Díazgranados JA; Oñate JM; Chavarriaga H; Herrera S; Parra B; Libreros G; Jaramillo R; Avendaño AC; Toro DF; Torres M; Lesmes MC; Rios CA; Caicedo I
    JAMA; 2021 Apr; 325(14):1426-1435. PubMed ID: 33662102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.